;PMID: 9216721
;source_file_2889.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..49] = [t:0..49]
;1)sentence:[e:55..158] = [t:55..158]
;2)section:[e:162..207] = [t:162..207]
;3)section:[e:211..308] = [t:211..308]
;4)sentence:[e:312..431] = [t:312..431]
;5)sentence:[e:432..677] = [t:432..677]
;6)sentence:[e:678..848] = [t:678..848]
;7)sentence:[e:849..936] = [t:849..936]
;8)sentence:[e:937..1137] = [t:937..1137]
;9)sentence:[e:1138..1186] = [t:1138..1186]
;10)sentence:[e:1187..1373] = [t:1187..1373]
;11)section:[e:1377..1421] = [t:1377..1421]

;section 0 Span:0..49
;Cancer Genet Cytogenet.  1997 Jul 15;96(2):134-9.
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..12] Genet) (NNP:[13..22] Cytogenet)
        (.:[22..23] .) (CD:[25..29] 1997) (CC:[30..33] Jul) (CD:[34..39] 15;96)
        (-LRB-:[39..40] -LRB-) (CD:[40..41] 2) (-RRB-:[41..42] -RRB-)
        (::[42..43] :) (CD:[43..46] 134) (::[46..47] -) (CD:[47..49] 9.)))

;sentence 1 Span:55..158
;Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence
; for two deleted regions.
;[55..77]:variation-type:"Loss of heterozygosity"
;[81..96]:variation-location:"chromosome 9p21"
;[100..107]:malignancy-clinical-stage:"primary"
;[108..122]:malignancy-type:"neuroblastomas"
(SENT
  (NP-HLN
    (NP
      
      (NP (NN:[55..59] Loss))
      (PP (IN:[60..62] of)
        (NP (NN:[63..77] heterozygosity)))
      (PP-LOC (IN:[78..80] at)
        (NP (NN:[81..91] chromosome) (NN:[92..96] 9p21)))
      (PP-LOC (IN:[97..99] in)
        (NP (JJ:[100..107] primary) (NNS:[108..122] neuroblastomas))))
    (::[122..123] :)
    (NP
      (NP (NN:[124..132] evidence))
      (PP (IN:[134..137] for)
        (NP (CD:[138..141] two) (VBN:[142..149] deleted)
            (NNS:[150..157] regions))))
    (.:[157..158] .)))

;section 2 Span:162..207
;Marshall B, Isidro G, Martins AG, Boavida MG.
(SEC
  (FRAG (NNP:[162..170] Marshall) (NNP:[171..172] B) (,:[172..173] ,)
        (NNP:[174..180] Isidro) (NNP:[181..182] G) (,:[182..183] ,)
        (NNP:[184..191] Martins) (NNP:[192..194] AG) (,:[194..195] ,)
        (NNP:[196..203] Boavida) (NNP:[204..207] MG.)))

;section 3 Span:211..308
;Departamento de Genetica Humana, Instituto Nacional de Saude Dr Ricardo
;Jorge,  Lisboa, Portugal.
(SEC
  (FRAG (NNP:[211..223] Departamento) (IN:[224..226] de)
        (NNP:[227..235] Genetica) (NNP:[236..242] Humana) (,:[242..243] ,)
        (NNP:[244..253] Instituto) (NNP:[254..262] Nacional) (IN:[263..265] de)
        (NNP:[266..271] Saude) (NNP:[272..274] Dr) (NNP:[275..282] Ricardo)
        (NNP:[283..288] Jorge) (,:[288..289] ,) (NNP:[291..297] Lisboa)
        (,:[297..298] ,) (NNP:[299..307] Portugal) (.:[307..308] .)))

;sentence 4 Span:312..431
;The genes responsible for the development of neuroblastoma following in vivo 
;deletion or mutation are largely unknown.
;[357..370]:malignancy-type:"neuroblastoma"
;[390..398]:variation-type:"deletion"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[312..315] The) (NNS:[316..321] genes))
      (ADJP (JJ:[322..333] responsible)
        (PP (IN:[334..337] for)
          (NP
            (NP
              (NP (DT:[338..341] the) (NN:[342..353] development))
              (PP (IN:[354..356] of)
                (NP (NN:[357..370] neuroblastoma))))
            (VP (VBG:[371..380] following)
              (NP
                (NP
                  (ADJP-1 (FW:[381..383] in) (FW:[384..388] vivo))
                  (NN:[390..398] deletion))
                (CC:[399..401] or)
                (NP
                  (ADJP-1 (-NONE-:[401..401] *P*))
                  (NN:[402..410] mutation))))))))
    (VP (VBP:[411..414] are)
      (ADVP (RB:[415..422] largely))
      (ADJP-PRD (JJ:[423..430] unknown)))
    (.:[430..431] .)))

;sentence 5 Span:432..677
;We have performed loss of  heterozygosity studies on a series of 24
;Portuguese primary neuroblastomas using  6 polymorphic markers located at
;chromosome 9p21 spanning the p16/MTS1/CDKN2,  p15/MTS2/CDKN2B, and the
;interferon alpha and beta genes.
;[450..473]:variation-type:"loss of  heterozygosity"
;[511..518]:malignancy-clinical-stage:"primary"
;[519..533]:malignancy-type:"neuroblastomas"
;[574..589]:variation-location:"chromosome 9p21"
;[603..606]:gene-rna:"p16"
;[607..611]:gene-rna:"MTS1"
;[612..617]:gene-rna:"CDKN2"
;[620..623]:gene-rna:"p15"
;[624..628]:gene-rna:"MTS2"
;[629..635]:gene-rna:"CDKN2B"
;[645..661]:gene-rna:"interferon alpha"
;[645..655]...[666..670]:gene-rna:"interferon"..."beta"
(SENT
  (S
    (NP-SBJ (PRP:[432..434] We))
    (VP (VBP:[435..439] have)
      (VP (VBN:[440..449] performed)
        (NP
          (NML
            (NML (NN:[450..454] loss))
            (PP (IN:[455..457] of)
              (NP (NN:[459..473] heterozygosity))))
          (NNS:[474..481] studies))
        (PP (IN:[482..484] on)
          (NP
            (NP (DT:[485..486] a) (NN:[487..493] series))
            (PP (IN:[494..496] of)
              (NP (CD:[497..499] 24) (JJ:[500..510] Portuguese)
                  (JJ:[511..518] primary) (NNS:[519..533] neuroblastomas)))))
        (S-MNR
          (NP-SBJ (-NONE-:[533..533] *))
          (VP (VBG:[534..539] using)
            (NP
              (NP
                (NP (CD:[541..542] 6) (JJ:[543..554] polymorphic)
                    (NNS:[555..562] markers))
                (VP (VBN:[563..570] located)
                  (NP (-NONE-:[570..570] *))
                  (PP-LOC (IN:[571..573] at)
                    (NP (NN:[574..584] chromosome) (NN:[585..589] 9p21)))))
              (VP (VBG:[590..598] spanning)
                (NP (DT:[599..602] the)
                  (NML
                    (NML
                      (NML (NN:[603..606] p16) (SYM:[606..607] /)
                           (NN:[607..611] MTS1) (SYM:[611..612] /)
                           (NN:[612..617] CDKN2))
                      (NML-2 (-NONE-:[617..617] *RNR*)))
                    (,:[617..618] ,)
                    (NML
                      (NML (NN:[620..623] p15) (SYM:[623..624] /)
                           (NN:[624..628] MTS2) (SYM:[628..629] /)
                           (NN:[629..635] CDKN2B))
                      (NML-2 (-NONE-:[635..635] *RNR*)))))
                (,:[635..636] ,) (CC:[637..640] and)
                (NP (DT:[641..644] the)
                  (NML
                    (NML
                      
                      (NML-1 (NN:[645..655] interferon))
                      (SYM:[656..661] alpha)
                      (NML-2 (-NONE-:[661..661] *RNR*)))
                    (CC:[662..665] and)
                    (NML
                      (NML-1 (-NONE-:[665..665] *P*))
                      (SYM:[666..670] beta)
                      (NML-2 (-NONE-:[670..670] *RNR*)))))
                (NML-2 (NNS:[671..676] genes))))))))
    (.:[676..677] .)))

;sentence 6 Span:678..848
;Loss of heterozygosity  was observed in 4 of the 24 tumors (17%), a somewhat
;lower percentage than a  previous study that identified patients by a mass
;screening program.
;[678..700]:variation-type:"Loss of heterozygosity"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[678..682] Loss))
      (PP (IN:[683..685] of)
        (NP (NN:[686..700] heterozygosity))))
    (VP (VBD:[702..705] was)
      (VP (VBN:[706..714] observed)
        (NP-1 (-NONE-:[714..714] *))
        (PP-LOC (IN:[715..717] in)
          (NP
            (NP
              (NP (CD:[718..719] 4))
              (PP (IN:[720..722] of)
                (NP (DT:[723..726] the) (CD:[727..729] 24)
                    (NNS:[730..736] tumors)))
              (PRN (-LRB-:[737..738] -LRB-)
                (NP (CD:[738..740] 17) (NN:[740..741] %))
                (-RRB-:[741..742] -RRB-)))
            (,:[742..743] ,)
            (NP
              (NP (DT:[744..745] a)
                (ADJP (RB:[746..754] somewhat) (JJR:[755..760] lower))
                (NN:[761..771] percentage))
              (PP (IN:[772..776] than)
                (NP
                  (NP (DT:[777..778] a) (JJ:[780..788] previous)
                      (NN:[789..794] study))
                  (SBAR
                    (WHNP-2 (WDT:[795..799] that))
                    (S
                      (NP-SBJ-2 (-NONE-:[799..799] *T*))
                      (VP (VBD:[800..810] identified)
                        (NP (NNS:[811..819] patients))
                        (PP-MNR (IN:[820..822] by)
                          (NP (DT:[823..824] a)
                            (NML (JJ:[825..829] mass) (NN:[830..839] screening))
                            (NN:[840..847] program)))))))))))))
    (.:[847..848] .)))

;sentence 7 Span:849..936
;A  correlation was also observed between 9p21 LOH and 1p36 LOH in our group
;of  tumors.
;[890..894]:variation-location:"9p21"
;[895..898]:variation-type:"LOH"
;[903..907]:variation-location:"1p36"
;[908..911]:variation-type:"LOH"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[849..850] A) (NN:[852..863] correlation))
      (PP-2 (-NONE-:[863..863] *ICH*)))
    (VP (VBD:[864..867] was)
      (ADVP (RB:[868..872] also))
      (VP (VBN:[873..881] observed)
        (NP-1 (-NONE-:[881..881] *))
        (PP-2 (IN:[882..889] between)
          (NP
            (NP (NN:[890..894] 9p21) (NN:[895..898] LOH))
            (CC:[899..902] and)
            (NP (NN:[903..907] 1p36) (NN:[908..911] LOH))))
        (PP (IN:[912..914] in)
          (NP
            (NP (PRP$:[915..918] our) (NN:[919..924] group))
            (PP (IN:[925..927] of)
              (NP (NNS:[929..935] tumors)))))))
    (.:[935..936] .)))

;sentence 8 Span:937..1137
;Two distinct regions of 9p21 deletion were observed: one located in the 
;region adjacent to the markers D9S162 and D9S1747 and a second located 
;centromerically of the p16 gene near the D9S171 marker.
;[961..965]:variation-location:"9p21"
;[966..974]:variation-type:"deletion"
;[1010..1059]:variation-location:"region adjacent to the markers D9S162 and
;D9S1747"
;[1082..1136]:variation-location:"centromerically of the p16 gene near the
;D9S171 marker"
;[1105..1108]:gene-rna:"p16"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (CD:[937..940] Two) (JJ:[941..949] distinct)
            (NNS:[950..957] regions))
        (PP (IN:[958..960] of)
          (NP (NN:[961..965] 9p21) (NN:[966..974] deletion))))
      (NP-2 (-NONE-:[974..974] *ICH*)))
    (VP (VBD:[975..979] were)
      (VP (VBN:[980..988] observed)
        (NP-1 (-NONE-:[988..988] *))
        (::[988..989] :)
        (NP-2
          (NP
            (NP (CD:[990..993] one))
            (VP (VBN:[994..1001] located)
              (NP (-NONE-:[1001..1001] *))
              (PP-LOC (IN:[1002..1004] in)
                (NP
                  (NP (DT:[1005..1008] the) (NN:[1010..1016] region))
                  (ADJP (JJ:[1017..1025] adjacent)
                    (PP (TO:[1026..1028] to)
                      (NP
                        (NP (DT:[1029..1032] the) (NNS:[1033..1040] markers))
                        (NP (NN:[1041..1047] D9S162) (CC:[1048..1051] and)
                            (NN:[1052..1059] D9S1747)))))))))
          (CC:[1060..1063] and)
          (NP
            (NP (DT:[1064..1065] a) (NN:[1066..1072] second))
            (VP (VBN:[1073..1080] located)
              (NP (-NONE-:[1080..1080] *))
              
              (ADVP (RB:[1082..1097] centromerically)
                (PP (IN:[1098..1100] of)
                  (NP (DT:[1101..1104] the) (NN:[1105..1108] p16)
                      (NN:[1109..1113] gene))))
              (PP (RB:[1114..1118] near)
                (NP (DT:[1119..1122] the) (NN:[1123..1129] D9S171)
                    (NN:[1130..1136] marker))))))))
    (.:[1136..1137] .)))

;sentence 9 Span:1138..1186
;The latter region is  exclusive of the p16 gene.
;[1177..1180]:gene-rna:"p16"
(SENT
  (S
    (NP-SBJ (DT:[1138..1141] The) (JJ:[1142..1148] latter)
            (NN:[1149..1155] region))
    (VP (VBZ:[1156..1158] is)
      (ADJP-PRD (JJ:[1160..1169] exclusive)
        (PP (IN:[1170..1172] of)
          (NP (DT:[1173..1176] the) (NN:[1177..1180] p16) (NN:[1181..1185] gene)))))
    (.:[1185..1186] .)))

;sentence 10 Span:1187..1373
;This result suggests the presence of at least one  other tumor suppressor
;gene at 9p21, apart from the p16 and p15 genes, which may  be of importance
;to the development of neuroblastoma.
;[1269..1273]:variation-location:"9p21"
;[1290..1293]:gene-rna:"p16"
;[1298..1301]:gene-rna:"p15"
;[1359..1372]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (DT:[1187..1191] This) (NN:[1192..1198] result))
    (VP (VBZ:[1199..1207] suggests)
      (NP
        (NP (DT:[1208..1211] the) (NN:[1212..1220] presence))
        (PP (IN:[1221..1223] of)
          (NP
            (NP
              (QP (IN:[1224..1226] at) (JJS:[1227..1232] least)
                  (CD:[1233..1236] one))
              (JJ:[1238..1243] other)
              (NML (NN:[1244..1249] tumor) (NN:[1250..1260] suppressor))
              (NN:[1261..1265] gene))
            (ADVP-3 (-NONE-:[1265..1265] *ICH*))))
        (PP-LOC (IN:[1266..1268] at)
          (NP (NN:[1269..1273] 9p21)))
        (,:[1273..1274] ,)
        (ADVP-3 (RB:[1275..1280] apart)
          (PP (IN:[1281..1285] from)
            (NP
              (NP (DT:[1286..1289] the)
                (NML
                  (NML (NN:[1290..1293] p16)
                    (NML-1 (-NONE-:[1293..1293] *P*)))
                  (CC:[1294..1297] and)
                  (NML (NN:[1298..1301] p15)
                    (NML-1 (NNS:[1302..1307] genes)))))
              (,:[1307..1308] ,)
              (SBAR
                (WHNP-2 (WDT:[1309..1314] which))
                (S
                  (NP-SBJ-2 (-NONE-:[1314..1314] *T*))
                  (VP (MD:[1315..1318] may)
                    (VP (VB:[1320..1322] be)
                      (PP-PRD (IN:[1323..1325] of)
                        (NP
                          (NP (NN:[1326..1336] importance))
                          (PP (TO:[1337..1339] to)
                            (NP
                              (NP (DT:[1340..1343] the)
                                  (NN:[1344..1355] development))
                              (PP (IN:[1356..1358] of)
                                (NP (NN:[1359..1372] neuroblastoma))))))))))))))))
    (.:[1372..1373] .)))

;section 11 Span:1377..1421
;PMID: 9216721 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1377..1381] PMID) (::[1381..1382] :) (CD:[1383..1390] 9216721)
        (NN:[1391..1392] -LSB-) (NNP:[1392..1398] PubMed) (::[1399..1400] -)
        (NN:[1401..1408] indexed) (IN:[1409..1412] for)
        (NNP:[1413..1421] MEDLINE-RSB-)))
